Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)

  • Michael H. Olsen
  • , Kristian Wachtell
  • , Jonathan N. Bella
  • , Jennifer E. Liu
  • , Kurt Boman
  • , Eva Gerdts
  • , Vasilios Papademetriou
  • , Markku S. Nieminen
  • , Jens Rokkedal
  • , Björn Dahlöf
  • , Richard B. Devereux

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Neither losartan- nor atenolol-based antihypertensive regimens could prevent the progression of aortic valve (AV) sclerosis in elderly, high-risk hypertensive patients, and the regression of AV sclerosis did not translate into reduced cardiovascular risk.

Original languageEnglish
Pages (from-to)1076-1080
Number of pages5
JournalAmerican Journal of Cardiology
Volume94
Issue number8
DOIs
StatePublished - 15 Oct 2004
Externally publishedYes

Fingerprint

Dive into the research topics of 'Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)'. Together they form a unique fingerprint.

Cite this